Acne severity

Acne severity refers to the clinical categorization of the extent and intensity of acne vulgaris, typically characterized by the presence of comedones, papules, pustules, and nodules [2][3]. It is not a specific molecular target like a receptor or enzyme; rather, it is a phenotypic manifestation of underlying pathological factors, including sebum overproduction, follicular hyperkeratinization, and inflammatory responses [1][5]. In clinical research, severity is quantified using standardized assessment tools like the Investigator Global Assessment (IGA) scale to determine the efficacy of new therapies [2][14]. These assessments allow for the classification of patients into mild, moderate, or severe groups, which often dictates the chosen therapeutic strategy [3][13]. While the severity itself is the measurement of the disease state, pharmacological interventions target the underlying biological drivers such as androgen signaling, inflammatory cytokines (e.g., IL-1β), and microbial colonization [1][10]. Understanding this distinction is essential for drug development, as reducing acne severity is the primary regulatory objective for achieving clinical approval [2][15]. Therefore, acne severity serves as the benchmark for evaluating the therapeutic success of treatments like retinoids, antibiotics, and hormonal modulators [10][13].

Other names

Acne vulgaris severityAcne gradingInvestigator Global Assessment (IGA) scoreGlobal Acne Grading System (GAGS)mGEA (modified Global Evaluation of Acne)Leeds Acne Grading SystemCook's Grading Scale

Not applicable as a molecular target; therapeutic interventions reduce clinical severity by normalizing follicular keratinization, decreasing sebum production, inhibiting Cutibacterium acnes proliferation, and suppressing pro-inflammatory pathways [1][9][10].